CA2532117C - Humanized immunoglobulin loci - Google Patents

Humanized immunoglobulin loci Download PDF

Info

Publication number
CA2532117C
CA2532117C CA2532117A CA2532117A CA2532117C CA 2532117 C CA2532117 C CA 2532117C CA 2532117 A CA2532117 A CA 2532117A CA 2532117 A CA2532117 A CA 2532117A CA 2532117 C CA2532117 C CA 2532117C
Authority
CA
Canada
Prior art keywords
human
spacer
humanized
gene
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2532117A
Other languages
English (en)
French (fr)
Other versions
CA2532117A1 (en
Inventor
Roland Buelow
Wim Van Schooten
Josef Platzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therapeutic Human Polyclonals Inc
Original Assignee
Therapeutic Human Polyclonals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutic Human Polyclonals Inc filed Critical Therapeutic Human Polyclonals Inc
Publication of CA2532117A1 publication Critical patent/CA2532117A1/en
Application granted granted Critical
Publication of CA2532117C publication Critical patent/CA2532117C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2532117A 2003-07-15 2004-07-15 Humanized immunoglobulin loci Expired - Lifetime CA2532117C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48773303P 2003-07-15 2003-07-15
US60/487,733 2003-07-15
PCT/US2004/023226 WO2005007696A2 (en) 2003-07-15 2004-07-15 Humanized immunoglobulin loci

Publications (2)

Publication Number Publication Date
CA2532117A1 CA2532117A1 (en) 2005-01-27
CA2532117C true CA2532117C (en) 2012-07-10

Family

ID=34079388

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2532117A Expired - Lifetime CA2532117C (en) 2003-07-15 2004-07-15 Humanized immunoglobulin loci

Country Status (10)

Country Link
US (4) US7585668B2 (https=)
EP (1) EP1644417B1 (https=)
JP (2) JP2007537704A (https=)
CN (2) CN1852925A (https=)
AU (1) AU2004257292A1 (https=)
CA (1) CA2532117C (https=)
ES (1) ES2473596T3 (https=)
IL (1) IL172885A0 (https=)
MX (1) MXPA06000562A (https=)
WO (1) WO2005007696A2 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1644417B1 (en) * 2003-07-15 2014-04-30 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
EP2029729A2 (en) * 2006-05-31 2009-03-04 Genzyme Corporation Methods of using anti-thymocyte globulin and related agents
US20090053210A1 (en) * 2006-09-01 2009-02-26 Roland Buelow Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
ATE536374T1 (de) * 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
DK2602323T3 (en) * 2007-06-01 2018-04-16 Open Monoclonal Tech Inc Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies
WO2009097006A2 (en) * 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
WO2009023800A1 (en) * 2007-08-14 2009-02-19 Origen Therapeutics Transgenic chickens with an inactivated endogenous gene locus
EP2108696A1 (en) * 2008-04-10 2009-10-14 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Cis-acting diversification activator and method for selective diversification of nucleic acids
JP5827127B2 (ja) * 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
BR112012000536A2 (pt) * 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
US8592644B2 (en) * 2009-08-13 2013-11-26 Crystal Bioscience Inc. Transgenic animal for production of antibodies having minimal CDRS
US8865462B2 (en) 2010-01-20 2014-10-21 Crystal Bioscience Inc. Sustained culture of avian gonocytes
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
KR102203727B1 (ko) 2010-03-31 2021-01-18 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
US9012717B2 (en) 2010-06-22 2015-04-21 Regeneron Pharmaceuticals, Inc. Human lambda light chain mice
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
CN102250239B (zh) * 2011-06-13 2013-04-17 中国农业科学院哈尔滨兽医研究所 一种与兔出血症病毒vp60蛋白相结合的蛋白及其应用
RS59728B1 (sr) 2011-08-05 2020-02-28 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
BR112014006394A2 (pt) * 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
KR20160098514A (ko) 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
RU2664181C2 (ru) 2011-12-20 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной легкой цепью
WO2013092720A1 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
RS62023B1 (sr) * 2012-02-01 2021-07-30 Regeneron Pharma Humanizovani glodari koji eksprimiraju teške lance koji sadrže vl domene
KR102228296B1 (ko) 2012-03-16 2021-03-17 리제너론 파마슈티칼스 인코포레이티드 히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
SG10201700360VA (en) 2012-03-16 2017-03-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
PT3597037T (pt) 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
KR102159163B1 (ko) 2012-08-03 2020-09-23 에스에이비, 엘엘씨 유전자삽입 동물에서 인간 항체의 제조를 위한 복합 염색체 조작
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
CN105189545A (zh) * 2013-03-13 2015-12-23 瑞泽恩制药公司 常见轻链小鼠
WO2014160202A1 (en) * 2013-03-13 2014-10-02 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
EP3092007A4 (en) * 2014-01-10 2017-06-07 Allermabs Co. Ltd. Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
KR102276752B1 (ko) 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
US20170058029A1 (en) * 2014-05-02 2017-03-02 Chiome Bioscience Inc. Human antibody-producing cell
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
CN113862300A (zh) * 2015-10-29 2021-12-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
WO2018128691A1 (en) * 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
WO2018104068A1 (en) 2016-12-05 2018-06-14 Koninklijke Philips N.V. Foreign object detection in a wireless power transfer system
NZ755816A (en) * 2017-01-19 2026-03-27 Omniab Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
WO2019129679A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
US20210000088A1 (en) * 2018-03-21 2021-01-07 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
JP7354306B2 (ja) 2019-06-27 2023-10-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
CN110540996B (zh) * 2019-08-29 2022-01-28 华中农业大学 一种克氏原螯虾i型溶菌酶gLysi2基因、其编码的gLysi2蛋白及其应用
WO2021127068A1 (en) * 2019-12-18 2021-06-24 Bristol-Myers Squibb Company Bcr transgenic mice with a common leader sequence
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
CN114854901B (zh) * 2022-06-22 2025-11-07 华南农业大学 与苦瓜全雌性状共分离的分子标记、引物及其应用
KR20260026086A (ko) 2023-06-21 2026-02-25 에프. 호프만-라 로슈 아게 Fap 표적화 림포톡신 베타 수용체 작용제를 이용한 조합 요법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001043A1 (en) 1990-07-10 1992-01-23 Nkk Corporation Hybridoma which produces avian specific immunoglobulin g
ATE300615T1 (de) * 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
WO1997016537A1 (en) 1995-10-30 1997-05-09 Spectral Diagnostics, Inc. Stable chicken b-cell line and method of use thereof
ATE307830T1 (de) 1999-02-05 2005-11-15 Therapeutic Human Polyclonals Aus nicht-menschlichen transgenen tieren gewonnene menschliche polyklonale antikörper
WO2000075300A2 (en) 1999-06-04 2000-12-14 Tranxenogen, Inc. Methods for manipulating the avian genome
WO2001019394A2 (en) 1999-09-15 2001-03-22 Therapeutic Human Polyclonals, Inc. Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
ATE430756T1 (de) 2002-06-26 2009-05-15 Transgenrx Inc Genregulation in transgenen tieren unter verwendung eines vektors auf transposonbasis
EP1644417B1 (en) * 2003-07-15 2014-04-30 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
EP1782360A4 (en) 2004-08-27 2009-03-18 Medic4All Ag METHOD AND SYSTEM FOR THE USE OF A MOBILE DEVICE AS A PORTABLE PERSONAL TERMINAL FOR MEDICAL INFORMATION
US20110077965A1 (en) 2009-09-25 2011-03-31 Cerner Innovation, Inc. Processing event information of various sources
US20120306653A1 (en) 2011-06-02 2012-12-06 Nokia Siemens Networks Oy Medical sensor
US20130021154A1 (en) 2011-07-21 2013-01-24 Solomon Clifford T Medical parameters notification system

Also Published As

Publication number Publication date
AU2004257292A1 (en) 2005-01-27
US8410333B2 (en) 2013-04-02
CN103205436B (zh) 2016-05-25
JP2011182801A (ja) 2011-09-22
US20130189774A1 (en) 2013-07-25
EP1644417B1 (en) 2014-04-30
ES2473596T3 (es) 2014-07-07
USRE47131E1 (en) 2018-11-20
EP1644417A2 (en) 2006-04-12
US20060026696A1 (en) 2006-02-02
US8652842B2 (en) 2014-02-18
IL172885A0 (en) 2006-06-11
CN103205436A (zh) 2013-07-17
US20100205682A1 (en) 2010-08-12
MXPA06000562A (es) 2006-03-30
CA2532117A1 (en) 2005-01-27
CN1852925A (zh) 2006-10-25
JP2007537704A (ja) 2007-12-27
WO2005007696A2 (en) 2005-01-27
JP6017763B2 (ja) 2016-11-02
US7585668B2 (en) 2009-09-08
WO2005007696A3 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
CA2532117C (en) Humanized immunoglobulin loci
AU2001284703B2 (en) Production of humanized antibodies in transgenic animals
RU2559524C2 (ru) Продуцирующие антитела млекопитающие, не являющиеся человеком
US20050153392A1 (en) Transgenesis with humanized immunoglobulin loci
US8354568B2 (en) Suppression of B-cell apoptosis in transgenic animals expressing humanized immunoglobulin
US20060117398A1 (en) Suppression of endogenous immunoglobulin expression
AU2001284703A1 (en) Production of humanized antibodies in transgenic animals
US20240373832A1 (en) Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
US20100235929A1 (en) Compositions and Methods for Producing Antibodies Having Human Idiotypes in Transgenic Birds
ZA200301723B (en) Production of humanized antibodies in transgenic animals.

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250117